Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
  1. Condition:   Neuroendocrine Carcinoma
    Interventions:   Drug: CPT-11;   Drug: Calcio levofolinate;   Drug: 5-Fluorouracil;   Drug: Capecitabine;   Drug: Temozolomide
    Sponsor:   Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
    Recruiting
  2. Condition:   Gastro-entero-pancreatic Neuroendocrine Tumors
    Interventions:   Drug: Capecitabine;   Drug: Lu-PRRT;   Drug: SS-LAR
    Sponsor:   Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
    Recruiting
  3. Conditions:   Neuroendocrine Tumors;   Progesterone Receptor Positive Tumor;   Estrogen Receptor Positive Tumor
    Intervention:   Drug: Tamoxifen
    Sponsor:   AC Camargo Cancer Center
    Recruiting
  4. Conditions:   Oncology;   Neuroendocrine Carcinoma
    Interventions:   Drug: Liposomal Irinotecan;   Drug: Fluorouracil;   Drug: Folinic Acid;   Drug: Docetaxel
    Sponsors:   The Christie NHS Foundation Trust;   University of Leeds;   Servier;   National Institute for Health Research, United Kingdom
    Recruiting
  5. Condition:   Gastro-Enteropancreatic Neuroendocrine Tumor
    Intervention:   Drug: Satoreotide trizoxetan
    Sponsor:   Ipsen
    Recruiting
  6. Conditions:   Pancreatic Tumours;   Midgut Neuroendocrine Tumours
    Intervention:   Drug: Lanreotide autogel 120 mg
    Sponsor:   Ipsen
    Recruiting
  7. Conditions:   Neuroendocrine Tumors;   Pancreatic Neuroendocrine Tumor;   Gastro-enteropancreatic Neuroendocrine Tumor;   Lung Neuroendocrine Neoplasm;   Neuroendocrine Carcinoma
    Intervention:   Drug: CVM-1118
    Sponsor:   TaiRx, Inc.
    Recruiting
  8. Conditions:   Poorly Differentiated Malignant Neuroendocrine Carcinoma;   Neuroendocrine Carcinoma, Grade 3;   Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
    Intervention:   Drug: Everolimus (Afinitor®)
    Sponsors:   AIO-Studien-gGmbH;   Assign Data Management and Biostatistics GmbH;   Novartis Pharmaceuticals
    Recruiting
  9. Conditions:   Neuroendocrine Tumor, Malignant;   Liver Metastases
    Interventions:   Device: Bland Embolization;   Combination Product: Transarterial chemoembolization;   Combination Product: Drug Eluting Beads Embolization
    Sponsors:   University of Pennsylvania;   Guerbet
    Recruiting
  10. Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Enterochromaffin Cell Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Functional Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Nonfunctional Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  11. Conditions:   Small Cell Carcinoma;   Carcinoma, Non-Small-Cell Lung;   Neuroendocrine Tumors;   Ovarian Epithelial Cancer
    Interventions:   Drug: RRx-001;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Irinotecan;   Drug: Vinorelbine;   Drug: Doxil;   Drug: Gemcitabine;   Drug: Taxane;   Drug: Paclitaxel;   Drug: Nab-Paclitaxel;   Drug: Pemetrexed
    Sponsor:   EpicentRx, Inc.
    Recruiting
  12. Conditions:   Neuroendocrine Tumors;   Carcinoma, Small Cell Lung;   Neuroendocrine Carcinoma
    Intervention:   Drug: PEN-221
    Sponsor:   Tarveda Therapeutics
    Recruiting
  13. Conditions:   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   Stage IV Prostate Cancer AJCC v7
    Interventions:   Procedure: CT (Computed Tomography);   Drug: Gallium Ga 68-DOTATATE;   Procedure: Positron Emission Tomography
    Sponsor:   Emory University
    Recruiting
  14. Condition:   Neuroendocrine Carcinoma
    Intervention:   Other: Lu-DOTA-TATE
    Sponsor:   Lawson Health Research Institute
    Recruiting
  15. Condition:   Neuroendocrine Tumors
    Interventions:   Drug: Cabozantinib;   Behavioral: Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   Exelixis
    Recruiting
  16. Conditions:   Neuroendocrine Tumors;   Neoplasm Metastasis;   Liver
    Intervention:   Procedure: D-TACE using CalliSpheres and Oxaliplatin
    Sponsor:   Xiangya Hospital of Central South University
    Recruiting
  17. Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  18. Conditions:   Pheochromocytoma;   Paraganglioma;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Ga-68-DOTATATE;   Drug: F-18-FDG;   Drug: Amino Acid solution
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  19. Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Cell Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Plasmacytoid Urothelial Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Sarcomatoid Urothelial Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  20. Conditions:   Carcinoma, Non-Small -Cell Lung;   Ovarian Neoplasms;   Small Cell Lung Carcinoma;   Uterine Cervical Neoplasms;   Carcinoma, Neuroendocrine;   Extrapulmonary Small Cell Cancer
    Interventions:   Drug: Topotecan;   Drug: VX-970
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  21. Condition:   Thyroid Cancer
    Intervention:   Drug: Regorafenib
    Sponsors:   Dana-Farber Cancer Institute;   Bayer
    Recruiting
  22. Conditions:   ATM Biallelic Inactivation;   ATM Gene Mutation;   ATM Monoallelic Inactivation;   BRCA1 Biallelic Inactivation;   BRCA1 Gene Mutation;   BRCA2 Biallelic Inactivation;   BRCA2 Gene Mutation;   FANCA Biallelic Inactivation;   Homologous Recombination Deficiency;   PALB2 Biallelic Inactivation;   PALB2 Gene Mutation;   Prostate Adenocarcinoma Without Evidence of Neuroendocrine Differentiation;   Stage I Prostate Cancer AJCC v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8
    Interventions:   Drug: Olaparib;   Procedure: Radical Prostatectomy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  23. Condition:   Advanced Cancer
    Intervention:   Biological: pembrolizumab
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  24. Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   MITF Positive;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  25. Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsor:   Loxo Oncology, Inc.
    Recruiting
  26. Condition:   Cushing's Syndrome
    Intervention:   Drug: osilodrostat
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  27. Condition:   Breast Cancer
    Interventions:   Drug: alpelisib;   Drug: fulvestrant;   Drug: letrozole
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  28. Condition:   Merkel Cell Carcinoma
    Intervention:   Drug: KRT-232
    Sponsor:   Kartos Therapeutics, Inc.
    Not yet recruiting
  29. Condition:   Merkel Cell Carcinoma
    Intervention:   Drug: Pembrolizumab (MK-3475)
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  30. Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8;   Resected Mass
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  31. Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIA Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7
    Interventions:   Biological: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  32. Conditions:   Adenoid Cystic Carcinoma;   Adnexal Carcinoma;   Apocrine Carcinoma;   Eccrine Porocarcinoma;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Non-Melanomatous Lesion;   Paget Disease;   Papillary Adenocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage III Skin Cancer;   Stage IV Skin Cancer;   Sweat Gland Carcinoma;   Trichilemmocarcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  33. Conditions:   Paraganglioma;   Gastrointestinal Stromal Tumors;   Carcinoma, Renal Cell;   Renal Neoplasms;   Pheochromocytoma
    Intervention:   Drug: SGI-110 (guadecitabine)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting